ABOUT CAIRN

Cairn Biosciences is developing next-generation therapeutics that address significant challenges in the treatment of serious diseases.

Cairn’s drug discovery engine addresses the profound unmet need for new tools to decipher cellular complexity and enable scalable discovery of groundbreaking therapies.

Our proprietary approach enables us to monitor multiple dynamic facets of previously inaccessible biology in live cells and fast-track the discovery of a pipeline of drugs for a wide range of indications with an initial focus on cancer.

MEET THE TEAM

Mary Ludlam PhD

Founder & CEO

Established biopharma R&D group leader
Serial drug discovery technology innovator
Expertise in cell biology, high-throughput microscopy and computational analysis
Critical role in multiple oncology programs including block-buster FDA-approved medicines

Duncan Parsons-Karavassilis PhD

VP Finance

& Operations

Experienced strategic change manager
Complex system development across multiple domains
Start-up product development management
Investment banking project management and new business implementation

Susana Abreu Ribeiro PhD

Associate Director

Paris Site Head

Development of state of the art technologies for complex cell biology
Expert in cell line engineering, live-cell microscopy and high-throughput CRISPR screening
Design and implementation of tools and technologies to profile multiple oncology pathways

Catherine Lacayo PhD

Associate Director

Platform Biology

Expert in probing dynamics & perturbations in diverse cell-based formats
Highly skilled in cell line engineering and quantitative live-cell microscopy
Broad assay development skillset encompassing mammalian & iPS cells applied to toxicity testing & disease modeling